Point-of-Care Diagnostics Market Hits $59B as Decentralized Healthcare Reshapes Patient Access

The healthcare industry is experiencing a fundamental structural shift away from traditional centralized delivery models, with the point-of-care diagnostics market reaching $58.76 billion globally in 2026. This represents a pivotal moment in how patients access medical services, characterized by rapid decentralization and the emergence of consumer-facing healthcare solutions. As the market expands at nearly 10% annually, industry leaders are positioning themselves to capture an expanding opportunity projected to reach $114.65 billion by 2035—a doubling of current market value in less than a decade.

This transition is being catalyzed by five companies that are fundamentally reimagining patient care delivery through technology, pharmaceuticals, and infrastructure innovation. The momentum reflects broader demographic trends, technological advancement, and shifting consumer preferences toward convenience and accessibility in healthcare.

Market Scale and Growth Trajectory

The $58.76 billion market in 2026 represents substantial progress in a sector that has gained momentum over the past five years. The projected growth to $114.65 billion by 2035 underscores investor confidence in point-of-care solutions as a durable, multi-year investment thesis.

Key market metrics include:

• Current market size: $58.76 billion (2026)
• Annual growth rate: ~10%
• Target market size: $114.65 billion (2035)
• Forecast period: 9 years
• Expected market doubling: Within decade

This growth trajectory significantly outpaces traditional healthcare infrastructure spending, suggesting that capital is actively flowing toward decentralized models. The consistent 10% compound annual growth rate indicates sustained demand rather than cyclical trends, which carries meaningful implications for companies positioned in this space.

Leading Companies Reshaping Healthcare Delivery

Five principal players are driving this transformation through distinct but complementary strategies:

VentriPoint Diagnostics is advancing AI-powered cardiac imaging with a global expansion strategy. By leveraging artificial intelligence to enhance diagnostic capabilities at the point of care, the company addresses a critical gap in cardiovascular assessment—a category representing billions in global healthcare spending. The integration of AI into diagnostic imaging enables faster, more accurate assessments outside traditional hospital settings, reducing delays in critical cardiac conditions.

Hims & Hers has partnered with Novo Nordisk to democratize access to GLP-1 medications, including the increasingly popular Wegovy treatment. This strategic collaboration is particularly significant given the explosive demand for weight-loss medications and the accessibility challenges patients face through traditional pharmacy channels. By offering affordable GLP-1 options through a direct-to-consumer telehealth model, Hims & Hers is capturing an enormous market segment previously served by expensive, limited-access channels. The partnership with Novo Nordisk, a pharmaceutical giant, validates the commercial viability of this model and provides supply chain stability.

MannKind is advancing inhaled insulin delivery through its Afrezza platform, with recent clinical data presentations strengthening its market position. Inhaled insulin represents a meaningful alternative to injectable insulin for diabetes management, addressing patient preference for non-injection routes while maintaining efficacy. The presentation of clinical evidence is crucial for expanding reimbursement coverage and adoption rates.

Ginkgo Bioworks has launched Cloud Lab, enabling remote access to autonomous laboratory infrastructure. This platform represents a significant infrastructure innovation—effectively decentralizing advanced scientific capabilities that previously required physical presence in specialized facilities. By democratizing access to autonomous lab infrastructure, Ginkgo Bioworks enables research, diagnostics, and drug development to occur remotely and at scale, fundamentally altering the cost structure of biological research and testing.

Market Context and Competitive Landscape

The rapid expansion of the point-of-care diagnostics market reflects convergent forces reshaping healthcare globally:

Regulatory Tailwinds: Healthcare regulators worldwide are accelerating approvals for decentralized diagnostics and telehealth solutions, particularly post-pandemic. The FDA, EMA, and other regulatory bodies have streamlined pathways for point-of-care devices and remote care delivery, reducing barriers to market entry.

Technological Enablement: Advances in miniaturization, AI, connectivity, and automation have made sophisticated diagnostics viable outside laboratory settings. The integration of machine learning with portable diagnostic devices enhances accuracy while reducing costs per test.

Consumer Demand: Patients increasingly prefer convenience, speed, and privacy in healthcare. The shift toward telemedicine and at-home testing gained momentum during the COVID-19 pandemic and has persisted as consumer expectations have permanently reset.

Cost Pressures: Healthcare systems globally face sustained cost pressures, making decentralized, preventive models attractive from a cost-per-outcome perspective. Point-of-care diagnostics typically reduce overall healthcare expenditure by enabling earlier intervention and reducing emergency department utilization.

Competitive Landscape: Traditional diagnostic companies like Quest Diagnostics and LabCorp face disruption from these emerging models. Meanwhile, technology companies including telehealth platforms and AI firms are increasingly entering diagnostics, intensifying competitive dynamics.

The sector is attracting significant capital from venture investors, strategic corporate acquirers, and public market participants, indicating confidence in the durability of these trends.

Investor Implications and Market Significance

For investors, the $59 billion market shift carries several critical implications:

Structural Growth: Unlike cyclical healthcare spending, point-of-care expansion appears structurally driven by lasting shifts in technology, regulation, and consumer preferences. This suggests the 10% CAGR may be sustainable or even conservative.

Multiple Expansion Potential: Companies successfully executing in this space may command premium valuations relative to traditional healthcare businesses due to higher growth rates and recurring revenue models from direct-to-consumer channels.

M&A Opportunity: As the market consolidates, larger healthcare, pharmaceutical, and technology conglomerates will likely acquire specialized point-of-care companies. Strategic acquirers can realize significant synergies by integrating these platforms into existing distribution networks.

Competitive Disruption Risk: Established diagnostic and pharmaceutical companies must adapt rapidly or risk losing market share to nimble decentralized competitors. This creates both investment opportunities and risks depending on execution.

Regulatory Dependency: The continued expansion of this market depends on favorable regulatory treatment. Changes in telemedicine reimbursement, pharmaceutical pricing regulation, or diagnostic approval standards could materially impact growth trajectories.

Broader Healthcare Transformation: This $59 billion market represents just one component of a broader shift toward value-based, preventive, and decentralized healthcare. Companies positioned at the intersection of diagnostics, pharmaceuticals, and direct consumer engagement may capture outsized economic value.

For equity investors with healthcare exposure, the question is no longer whether decentralized care will grow, but rather which companies will successfully scale these models while maintaining unit economics and regulatory compliance. The companies listed above represent early movers with distinct competitive advantages, though execution risk remains substantial given the nascent nature of many platforms.

Looking Forward

The $58.76 billion point-of-care market in 2026 marks an inflection point rather than a plateau. The trajectory toward $114.65 billion by 2035 suggests this structural shift will accelerate, driven by continuing technological advancement, regulatory evolution, and consumer adoption. VentriPoint, Hims & Hers, MannKind, and Ginkgo Bioworks are positioned to benefit significantly from this expansion, though competition will intensify as larger incumbents respond.

Investors should monitor several key metrics: adoption rates among consumers and healthcare providers, reimbursement trends from major payers, clinical evidence supporting new technologies, and M&A activity within the sector. The companies leading this transformation today may define healthcare delivery for the next decade, making careful attention to execution quality and market dynamics essential for portfolio allocation decisions.